Abstract
Despite the attractiveness of a vaccination strategy for the treatment of high blood pressure, and many decades of research, attempts to translate this strategy to hypertension management have been unsuccessful. Immunization against components of the renin angiotensin system offers the prospect of improved long-term control of hypertension because efficacy does not require daily compliance with oral medication. Moreover, such a strategy may provide therapeutic benefits beyond blood pressure control, such as improved prevention and treatment of heart failure, and cardiovascular, cerebrovascular, and renal disease. However, despite these potential advantages, there are a number of concerns about the safety and efficacy of this approach. Renin immunization demonstrated effective blood pressure reduction in animal models of hypertension but was accompanied by autoimmune disease of the kidney. Moreover, there are theoretical arguments that angiotensin immunization may have limited effectiveness and clinical studies confirmed these limitations. Vaccination against the angiotensin II type 1 receptor is another possible approach but has yet to undergo clinical evaluation. Thus, the role of vaccination against renin angiotensin system components in hypertension management remains to be established.
Keywords: Angiotensin I, angiotensin II, angiotensin II type 1 receptor, renin, immunization, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, vaccination, high blood pressure, autoimmune disease
Current Pharmaceutical Design
Title: Vaccination Against High Blood Pressure
Volume: 18 Issue: 7
Author(s): Duncan J. Campbell
Affiliation:
Keywords: Angiotensin I, angiotensin II, angiotensin II type 1 receptor, renin, immunization, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, vaccination, high blood pressure, autoimmune disease
Abstract: Despite the attractiveness of a vaccination strategy for the treatment of high blood pressure, and many decades of research, attempts to translate this strategy to hypertension management have been unsuccessful. Immunization against components of the renin angiotensin system offers the prospect of improved long-term control of hypertension because efficacy does not require daily compliance with oral medication. Moreover, such a strategy may provide therapeutic benefits beyond blood pressure control, such as improved prevention and treatment of heart failure, and cardiovascular, cerebrovascular, and renal disease. However, despite these potential advantages, there are a number of concerns about the safety and efficacy of this approach. Renin immunization demonstrated effective blood pressure reduction in animal models of hypertension but was accompanied by autoimmune disease of the kidney. Moreover, there are theoretical arguments that angiotensin immunization may have limited effectiveness and clinical studies confirmed these limitations. Vaccination against the angiotensin II type 1 receptor is another possible approach but has yet to undergo clinical evaluation. Thus, the role of vaccination against renin angiotensin system components in hypertension management remains to be established.
Export Options
About this article
Cite this article as:
J. Campbell Duncan, Vaccination Against High Blood Pressure, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436511
DOI https://dx.doi.org/10.2174/138161212799436511 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease
Current Pharmaceutical Design Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Pancreatic Cancer: Promises and Failures of Target Therapies
Reviews on Recent Clinical Trials Design and In Vitro Evaluations of Sublingual Tablet of Timolol Maleate
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population
Current Neurovascular Research Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism Literature Review on Diabetes Internet-based Spanish-Language Information
Current Diabetes Reviews Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry The Potential Role of Angiotensin Converting Enzyme and Vasopeptidase Inhibitors in the Treatment of Diabetic Neuropathy
Current Drug Targets Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Outcome Measures for Clinical Trials in Interstitial Lung Diseases
Current Respiratory Medicine Reviews Mapracorat, a Novel Non-Steroidal Selective Glucocorticoid Receptor Agonist for the Treatment of Allergic Conjunctivitis
Inflammation & Allergy - Drug Targets (Discontinued) Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Mechanism Underlying the Formation of a Cluster of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets